Clinical Trial Update: Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study [Phase 2]

View source ↗

Summary

An extension Phase 2 trial evaluating safety and immunogenicity of a revaccination dose of the RSVPreF3 OA investigational vaccine in adults 60+ who previously …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSVPreF3 OA (RSV prefusion F protein vaccine for older adults)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED | Results posted: 2022-06-29